Can I go home now? The safety and efficacy of a new UK paediatric febrile neutropenia protocol for risk-stratified early discharge on oral antibiotics

Arch Dis Child. 2023 Mar;108(3):192-197. doi: 10.1136/archdischild-2021-323254. Epub 2022 Dec 12.

Abstract

Objective: To evaluate a new protocol of risk stratification and early discharge for children with febrile neutropenia (FN).

Design: Prospective service evaluation from 17 April 2020 to 16 April 2021.

Setting: 13 specialist centres in the UK.

Patients: 405 children presenting with FN.

Intervention: All children received intravenous antibiotics at presentation. Risk stratification was determined using the Australian-UK-Swiss (AUS) rule and eligibility for homecare assessed using criteria including disease, chemotherapy, presenting features and social factors. Those eligible for homecare could be discharged on oral antibiotics after a period of observation proportional to their risk group.

Main outcome measures: Median duration of admission and of intravenous antibiotics, and percentage of patients with positive blood cultures, significant infection, readmission within 7 days of initial presentation, intensive care unit (ICU) admission, death from infection and death from other causes.

Results: 13 centres contributed 729 initial presentations of 405 patients. AUS rule scores were positively correlated with positive blood cultures, significant infection, ICU admission and death. 20% of children were eligible for homecare with oral antibiotics, of which 55% were low risk (AUS 0-1). 46% low-risk homecare eligible patients were discharged by 24 hours vs 2% homecare ineligible. Homecare readmission rates were 14% overall and 16% for low-risk cases (similar to a meta-analysis of previous studies). No child eligible for homecare was admitted to ICU or died.

Conclusions: Use of the AUS rule and homecare criteria allow for safe early outpatient management of children with FN.

Keywords: infectious disease medicine; paediatrics.

MeSH terms

  • Anti-Bacterial Agents / adverse effects
  • Australia / epidemiology
  • Child
  • Febrile Neutropenia*
  • Humans
  • Meta-Analysis as Topic
  • Neoplasms* / drug therapy
  • Patient Discharge
  • Prospective Studies
  • United Kingdom

Substances

  • Anti-Bacterial Agents